Academic Journal
Προβολή σε EDS

Envafolimab - novel anti-PD-1/PD-L1 antibody in cancer treatment.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Envafolimab - novel anti-PD-1/PD-L1 antibody in cancer treatment.
Συγγραφείς: Kciuk M; Department of Molecular Biotechnology and Genetics, University of Lodz, Lodz, Poland.; Department of Functional Genomics, Faculty of Medicine, Medical University of Lodz, Lodz, Poland., Kołat D; Department of Molecular Biotechnology and Genetics, University of Lodz, Lodz, Poland.; Department of Functional Genomics, Faculty of Medicine, Medical University of Lodz, Lodz, Poland., Wanke K; Department of Molecular Biotechnology and Genetics, University of Lodz, Lodz, Poland.; Doctoral School of Exact and Natural Sciences, University of Lodz, Lodz, Poland., Kontek R; Department of Molecular Biotechnology and Genetics, University of Lodz, Lodz, Poland.
Πηγή: Frontiers in immunology [Front Immunol] 2026 Aug 05; Vol. 17, pp. 1918429. Date of Electronic Publication: 2026 Aug 05 (Print Publication: 2026).
Τύπος έκδοσης: Journal Article; Review
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Imprint Name(s): Original Publication: [Lausanne : Frontiers Research Foundation]
Ιατρικοί όροι (MeSH): Neoplasms*/drug therapy , Neoplasms*/immunology , Neoplasms*/metabolism , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/immunology , B7-H1 Antigen*/antagonists & inhibitors , B7-H1 Antigen*/immunology , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/adverse effects , Immune Checkpoint Inhibitors*/pharmacology , Antibodies, Monoclonal, Humanized*/therapeutic use , Antineoplastic Agents, Immunological*/therapeutic use, Immunotherapy/methods ; Humans ; Animals
Περίληψη: The landscape of immunotherapy in oncology has markedly advanced with the development of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors, fundamentally reshaping cancer treatment by potentiating anti-tumor immune responses. PD-1/PD-L1 blockade agents, such as FDA-approved nivolumab, pembrolizumab, and dostarlimab, have demonstrated significant clinical efficacy across various malignancies. Additionally, investigational agents like envafolimab, a novel PD-L1 inhibitor, are currently under clinical evaluation for efficacy and safety in solid tumors. This review examines the emerging data on envafolimab and discusses strategies to optimize its therapeutic impact, including combination regimens and personalized approaches. Tailoring treatments based on individual genetic, immunological, and microbiome profiles holds the potential to enhance response rates and the durability of outcomes. The integration of these factors is pivotal in advancing the precision and success of immunotherapy in oncology.
(Copyright © 2026 Kciuk, Kołat, Wanke and Kontek.)
Competing Interests: The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References: Front Immunol. 2023 Jan 31;14:1128774. (PMID: 36798129)
Cell Biosci. 2022 Jun 7;12(1):85. (PMID: 35672862)
Int J Mol Sci. 2022 Dec 06;23(23):. (PMID: 36499710)
JAMA Oncol. 2019 Apr 01;5(4):471-478. (PMID: 30589920)
Int J Oncol. 2022 Nov;61(5):. (PMID: 36129152)
Nat Immunol. 2011 Jun;12(6):492-9. (PMID: 21739672)
Front Immunol. 2022 Jun 30;13:888713. (PMID: 35844605)
J Oncol. 2019 Dec 11;2019:3267207. (PMID: 31885572)
BMJ Med. 2022 Oct 31;1(1):e000152. (PMID: 36936577)
Adv Immunol. 2014;122:91-128. (PMID: 24507156)
Front Immunol. 2022 Jan 24;13:809761. (PMID: 35140720)
Oncologist. 2021 Sep;26(9):e1514-e1525. (PMID: 33973293)
Front Genet. 2022 Nov 21;13:963964. (PMID: 36479248)
Cancer Lett. 2019 Apr 10;447:41-47. (PMID: 30684593)
Immunotherapy. 2017 Mar;9(3):289-302. (PMID: 28231720)
Front Immunol. 2025 Aug 27;16:1619043. (PMID: 40936903)
Exp Cell Res. 2014 Apr 1;322(2):345-54. (PMID: 24530475)
Int J Mol Sci. 2023 Sep 14;24(18):. (PMID: 37762416)
Mol Cancer Ther. 2011 Jul;10(7):1194-206. (PMID: 21566061)
Acta Medica (Hradec Kralove). 2010;53(2):73-7. (PMID: 20672742)
Cells. 2023 Feb 07;12(4):. (PMID: 36831197)
Nat Commun. 2014 Nov 26;5:5513. (PMID: 25423885)
Cell Biosci. 2023 Oct 13;13(1):188. (PMID: 37828613)
World J Gastrointest Oncol. 2022 Sep 15;14(9):1665-1674. (PMID: 36187397)
Cancer Res. 2006 Sep 15;66(18):9211-20. (PMID: 16982765)
Drugs. 2022 Feb;82(2):235-240. (PMID: 35122636)
Target Oncol. 2023 Jan;18(1):129-138. (PMID: 36482151)
J Cell Mol Med. 2019 Aug;23(8):4854-4865. (PMID: 31210425)
Signal Transduct Target Ther. 2024 Oct 9;9(1):280. (PMID: 39384742)
Trends Immunol. 2020 Aug;41(8):676-691. (PMID: 32622854)
Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):227-241. (PMID: 32417409)
BMC Cancer. 2024 Jul 19;24(1):869. (PMID: 39030523)
Eur J Med Chem. 2021 Jun 5;218:113356. (PMID: 33773287)
N Engl J Med. 2015 Jun 25;372(26):2509-20. (PMID: 26028255)
JCO Oncol Pract. 2023 May;19(5):251-259. (PMID: 36862965)
Front Cell Dev Biol. 2023 Feb 14;11:1116805. (PMID: 36866275)
Int J Mol Sci. 2020 May 30;21(11):. (PMID: 32486270)
Cancer. 2018 Apr 15;124(8):1650-1659. (PMID: 29315503)
Oncologist. 2025 Sep 1;30(9):. (PMID: 40658469)
Immunotherapy. 2018 Feb 1;10(4):299-316. (PMID: 29421979)
Aging Cell. 2022 Aug;21(8):e13668. (PMID: 35818124)
J Exp Clin Cancer Res. 2022 Feb 19;41(1):68. (PMID: 35183252)
Cancer Res. 2008 Nov 1;68(21):8643-53. (PMID: 18974103)
Int J Surg. 2025 Jan 01;111(1):334-345. (PMID: 39093871)
Expert Opin Biol Ther. 2019 Dec;19(12):1247-1263. (PMID: 31642347)
Biochem Biophys Res Commun. 2006 Dec 22;351(3):658-63. (PMID: 17083915)
JAMA Netw Open. 2023 May 1;6(5):e2311181. (PMID: 37129893)
Adv Med Sci. 2023 Sep;68(2):464-473. (PMID: 37926002)
Cells. 2023 Jan 19;12(3):. (PMID: 36766706)
Transl Oncol. 2022 May;19:101366. (PMID: 35219093)
Ann Med Surg (Lond). 2022 Jun 25;79:104047. (PMID: 35860105)
Invest New Drugs. 2025 Apr;43(2):181-190. (PMID: 39883265)
Front Oncol. 2025 Jan 10;14:1502945. (PMID: 39868378)
J Hematol Oncol. 2019 May 31;12(1):54. (PMID: 31151482)
Int J Colorectal Dis. 2025 Jan 21;40(1):20. (PMID: 39836256)
Trends Cancer. 2022 Nov;8(11):944-961. (PMID: 35853825)
Onco Targets Ther. 2019 Dec 12;12:10903-10916. (PMID: 31849494)
Oncologist. 2024 Sep 6;29(9):e1189-e1200. (PMID: 38982653)
Cancer Med. 2024 Apr;13(7):e7175. (PMID: 38597130)
BMC Med. 2025 Oct 6;23(1):535. (PMID: 41053707)
J Immunol. 2009 Feb 15;182(4):2102-12. (PMID: 19201863)
Target Oncol. 2024 Jul;19(4):601-610. (PMID: 38691294)
Mol Cell. 2019 Nov 7;76(3):359-370. (PMID: 31668929)
Recent Results Cancer Res. 2018;211:45-56. (PMID: 30069758)
BMC Cancer. 2021 Nov 25;21(1):1271. (PMID: 34819027)
Biomed Pharmacother. 2023 Jun;162:114646. (PMID: 37011483)
Int J Mol Sci. 2022 Aug 05;23(15):. (PMID: 35955855)
Invest New Drugs. 2022 Oct;40(5):1021-1031. (PMID: 35932387)
Drugs. 2018 Feb;78(2):155-162. (PMID: 29350327)
Cancer. 2025 Dec 15;131(24):e70203. (PMID: 41351845)
Front Immunol. 2021 Oct 05;12:750542. (PMID: 34675933)
Gynecol Oncol. 2020 Mar;156(3):669-675. (PMID: 31924330)
J Exp Med. 2014 May 5;211(5):781-90. (PMID: 24778419)
Gut. 2021 Jan;70(1):148-156. (PMID: 32350089)
J Immunother Cancer. 2020 Mar;8(1):. (PMID: 32217756)
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. (PMID: 38230766)
Front Immunol. 2022 May 12;13:886931. (PMID: 35634343)
Biomedicines. 2023 Jan 09;11(1):. (PMID: 36672677)
Thorac Cancer. 2025 Jun;16(12):e70101. (PMID: 40524516)
Cancers (Basel). 2023 Feb 06;15(4):. (PMID: 36831367)
SAGE Open Med. 2021 Aug 12;9:20503121211034366. (PMID: 34408877)
Cancer Discov. 2017 Mar;7(3):264-276. (PMID: 28031159)
Oncol Lett. 2023 Jun 30;26(2):351. (PMID: 37545619)
Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):12866-72. (PMID: 22753480)
Clin Cancer Res. 2021 Dec 15;27(24):6709-6715. (PMID: 34593531)
Transl Lung Cancer Res. 2022 Feb;11(2):213-223. (PMID: 35280306)
Science. 2016 Mar 25;351(6280):1463-9. (PMID: 26940869)
BMC Immunol. 2024 Sep 14;25(1):60. (PMID: 39271997)
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361-375. (PMID: 30886395)
Front Oncol. 2022 Oct 06;12:1002957. (PMID: 36276103)
J Hematol Oncol. 2021 Jun 21;14(1):95. (PMID: 34154614)
Mol Cancer Res. 2018 Aug;16(8):1209-1214. (PMID: 29592896)
Front Immunol. 2025 Jan 28;16:1505195. (PMID: 39958361)
Cell Discov. 2017 Mar 07;3:17004. (PMID: 28280600)
Am Soc Clin Oncol Educ Book. 2018 May 23;38:239-247. (PMID: 30231358)
PLoS One. 2016 Jun 09;11(6):e0157164. (PMID: 27281029)
Cancers (Basel). 2020 Nov 06;12(11):. (PMID: 33172030)
Cancer Treat Res. 2023;185:49-58. (PMID: 37306903)
Expert Opin Biol Ther. 2022 Oct;22(10):1227-1232. (PMID: 36124972)
Mol Immunol. 2017 Jul;87:227-239. (PMID: 28511092)
Immunotherapy. 2023 Jul;15(10):699-701. (PMID: 37139962)
Front Immunol. 2021 Feb 02;11:622509. (PMID: 33633741)
Neoplasia. 2023 Feb;36:100867. (PMID: 36563632)
Cancer Med. 2026 Apr;15(4):e71756. (PMID: 41891390)
Oxf Open Immunol. 2023 Jul 08;4(1):iqad006. (PMID: 37554723)
J Hematol Oncol. 2021 Jun 12;14(1):92. (PMID: 34118979)
Front Immunol. 2022 Mar 23;13:867098. (PMID: 35401556)
Sci Immunol. 2025 Jan 17;10(103):eadf4726. (PMID: 39823318)
Invest New Drugs. 2025 Feb;43(1):18-29. (PMID: 39690337)
Vaccines (Basel). 2023 Dec 20;12(1):. (PMID: 38276666)
Lancet Oncol. 2017 Sep;18(9):1182-1191. (PMID: 28734759)
Front Pharmacol. 2023 Mar 14;14:1113378. (PMID: 37007004)
Curr Cancer Drug Targets. 2025;25(6):648-664. (PMID: 39021191)
World J Gastroenterol. 2019 May 28;25(20):2416-2429. (PMID: 31171886)
Cancers (Basel). 2021 May 07;13(9):. (PMID: 34067105)
Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):168-75. (PMID: 23849696)
Cancers (Basel). 2021 Dec 23;14(1):. (PMID: 35008215)
Immunol Rev. 2024 Nov;328(1):98-112. (PMID: 39166870)
Exp Hematol Oncol. 2022 Nov 16;11(1):101. (PMID: 36384676)
J Pharm Sci. 2026 Jan;115(1):104026. (PMID: 41093037)
Bull Cancer. 2017 Jan;104(1):42-51. (PMID: 27979364)
Oncotarget. 2015 Jun 10;6(16):14209-19. (PMID: 25895031)
Nat Commun. 2017 Nov 24;8(1):1751. (PMID: 29170499)
Nat Rev Immunol. 2019 Nov;19(11):665-674. (PMID: 31570879)
Cancer Treat Rev. 2012 Apr;38(2):89-100. (PMID: 21715099)
Biomedicines. 2022 Jan 19;10(2):. (PMID: 35203421)
Hum Vaccin Immunother. 2023 Dec 31;19(1):2178220. (PMID: 36762991)
Mol Cancer. 2024 May 18;23(1):108. (PMID: 38762484)
Oncologist. 2022 Nov 3;27(11):e899-e907. (PMID: 36099421)
Cancer. 2021 May 15;127(10):1553-1567. (PMID: 33620731)
Br J Pharmacol. 2026 Mar;183(6):1207-1214. (PMID: 41435872)
Hum Vaccin Immunother. 2019;15(5):1111-1122. (PMID: 30888929)
Biology (Basel). 2021 Apr 29;10(5):. (PMID: 33946684)
Cancer Immunol Immunother. 2022 Mar;71(3):507-526. (PMID: 34355266)
Curr Pharm Des. 2018;24(41):4911-4920. (PMID: 30417781)
Cancer Cell. 2015 Apr 13;27(4):439-49. (PMID: 25858803)
Int J Cancer. 2016 Jul 15;139(2):396-403. (PMID: 26945902)
Life (Basel). 2022 Feb 02;12(2):. (PMID: 35207516)
Cancers (Basel). 2023 May 11;15(10):. (PMID: 37345057)
Front Oncol. 2022 Jan 26;12:729250. (PMID: 35155221)
ACS Appl Mater Interfaces. 2026 Jan 28;18(3):4979-4994. (PMID: 41548132)
Oncotarget. 2021 Aug 31;12(18):1802-1810. (PMID: 34504652)
Mol Cancer. 2025 May 7;24(1):136. (PMID: 40336045)
Mol Cancer. 2020 Aug 6;19(1):120. (PMID: 32762681)
Int Immunopharmacol. 2022 Mar;104:108469. (PMID: 35008005)
Int J Mol Sci. 2022 Jan 20;23(3):. (PMID: 35163049)
J Immunother Cancer. 2022 Jul;10(7):. (PMID: 35793867)
Biomed Pharmacother. 2023 Nov;167:115622. (PMID: 37783155)
Cell Death Discov. 2024 Apr 22;10(1):189. (PMID: 38649701)
Mol Cancer. 2019 Jan 15;18(1):10. (PMID: 30646912)
J Exp Clin Cancer Res. 2022 Jul 2;41(1):216. (PMID: 35780178)
Clinics (Sao Paulo). 2018 Dec 10;73(suppl 1):e557s. (PMID: 30540123)
FEBS J. 2021 Nov;288(21):6174-6186. (PMID: 33492779)
Contributed Indexing: Keywords: antibodies; cancer; envafolimab; immunotherapy; programmed cell death
Substance Nomenclature: 0 (Programmed Cell Death 1 Receptor)
0 (B7-H1 Antigen)
0 (Immune Checkpoint Inhibitors)
0 (Antibodies, Monoclonal, Humanized)
0 (Antineoplastic Agents, Immunological)
0 (CD274 protein, human)
0 (PDCD1 protein, human)
Entry Date(s): Date Created: 20260820 Date Completed: 20260820 Latest Revision: 20260828
Update Code: 20260829
PubMed Central ID: PMC13487507
DOI: 10.3389/fimmu.2026.1918429
PMID: 42621259
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1664-3224
DOI:10.3389/fimmu.2026.1918429